Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trialResearch in context

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trialResearch in context

Summary: Background: This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small–cell lung cancer (ES-SCLC). Biomarkers...

Full description

Bibliographic Details
Main Authors: Dawei Chen, Bing Zou, Butuo Li, Aiqin Gao, Wei Huang, Qian Shao, Xiangjiao Meng, Pinliang Zhang, Xiaoyong Tang, Xudong Hu, Yan Zhang, Jun Guo, Changhong Zhao, Jiajia Yuan, Qian Li, Changbin Zhu, Jinming Yu, Linlin Wang
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:EClinicalMedicine
Subjects:
Adebrelimab
Radiotherapy
Immunotherapy
Predictive biomarker
ES-SCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024003742

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024003742

Similar Items